Create an Account
  1. Home
  2. Specialty
  3. Retina

Exploring the Connection Between Anatomic and Visual Outcomes in Retinal Diseases

67839Thumb
Media formats available:
Details
Presenters

  • Overview

    Imaging biomarkers and novel advances in therapies have the potential to revolutionize treatment of neovascular age-related macular degeneration (nAMD) and other retinal diseases such as diabetic macular edema (DME) and retinal vein occlusion (RVO). 

    Hear from Karl Csaky, MD, PhD; Sophie J. Bakri, MD; and Avni P. Finn, MD, MBA, on how to assess the correlation between imaging biomarkers and functional outcomes in nAMD, DME, and RVO and how they are translating this knowledge into individualized treatment decisions for patients.

  • Commercial Support

    This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Assess the correlation between anatomic measures of disease activity and visual outcomes in retinal vascular diseases
    • Appraise anatomic and visual outcomes gained from second-generation treatments for retinal vascular diseases
    • Implement an evidence-based approach to individualize treatment for patients with retinal vascular diseases

  • Accreditation and Credit Designation Statements

    Provided by Evolve Medical Education 

    Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    Evolve designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Faculty

    Karl Csaky, MD, PhD

    Karl Csaky, MD, PhD

    T. Boone Pickens Director
    Molecular Ophthalmology Laboratory
    Chief Executive and Medical Officer 
    Retina Foundation of the Southwest
    Dallas, TX

     

    Sophie J. Bakri, MD

    Sophie J. Bakri, MD

    Chair and Professor of Ophthalmology
    Mayo Clinic
    Rochester, MN

     

    Avni P. Finn, MD, MBA

    Avni P. Finn, MD, MBA

    Assistant Professor
    Vanderbilt Eye Institute
    Nashville, TN

  • Disclosure of Relevant Financial Relationships

    DISCLOSURE POLICY
    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

    The following faculty/staff members have the following financial relationships with ineligible companies.

    Karl Csaky, MD, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Adverum Biothechnologies, Annexon Biosciences, Boehringer Ingelheim, EyeBio, Genentech, Heidelberg Engineering, Johnson & Johnson Vision, Merck, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Regeneron, Roche, and TenPoint Therapeutics. Grant/Research Support: Annexon Biosciences, Boehringer Ingelheim, Genentech, Gyroscope, NGM Biopharmaceuticals, and Novartis. Speaker's Bureau: Genentech.

    Sophie J. Bakri, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Adverum, Allergan, Amgen, Annexon Biosciences, Apellis Pharmaceuticals, Aviceda, Carl Zeiss Meditec, Cholgene, EyePoint Pharmaceuticals, Ilumen, Iveric Bio, Kala, Genentech, Neurotech, Novartis, Ocular Therapeutix, Opthea, Outlook, Pixium, Regeneron, Regenxbio, Rejuvitas, Revana, Roche, and VoxelCloud. Grant/Research Support: Lowy Medical Foundation and Regenxbio.

    Avni P. Finn, MD, MBA, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Apellis Pharmaceuticals, EyePoint Pharmaceuticals, Genentech, and Iveric Bio.

    The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.

  • Disclaimer

    OFF-LABEL STATEMENT
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Regeneron.

    This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00
    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free